Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Larisa V, Gubareva"'
Autor:
Krista Kniss, Juan A. De La Cruz, Anton Chesnokov, Larisa V. Gubareva, Angiezel Merced-Morales, Jennifer Laplante, Kirsten St. George, David E. Wentworth, Rebecca Kondor, Teena Mohan, Ha T. Nguyen, Vasiliy P. Mishin, Patricia A. Blevins
Publikováno v:
Emerging Infectious Diseases, Vol 27, Iss 7, Pp 1953-1957 (2021)
Emerging Infectious Diseases
Emerging Infectious Diseases
Four cases of oseltamivir-resistant influenza A(H1N1)pdm09 virus infection were detected among inhabitants of a border detention center in Texas, USA. Hemagglutinin of these viruses belongs to 6B.1A5A-156K subclade, which may enable viral escape from
Autor:
Le Thi Thanh, Le Quynh Mai, Amanda Balish, James C. Kile, Ngo Thu Huong, Adrian Creanga, Vuong Duc Cuong, Nguyen Co Thach, Nguyen Hoang Dang, Larisa V. Gubareva, Alexander Klimov, Mai Thuy Duong, Bryan K. Kapella, Hoang Vu Mai Phuong, C. Todd Davis, Nguyen Tran Hien, Ha T. Nguyen, Yunho Jang, Pham Thi Hien, Nguyen Le Khanh Hang, Nguyen Dang Tho, Nguyen Thanh Tung, Do Ngoc Hoa
Publikováno v:
The Journal of Infectious Diseases. 216:S529-S538
Mutation and reassortment of highly pathogenic avian influenza A(H5N1) viruses at the animal-human interface remain a major concern for emergence of viruses with pandemic potential. To understand the relationship of H5N1 viruses circulating in poultr
Autor:
James Stevens, Zhu Guo, Hua Yang, Tatiana Baranovich, Katrina Sleeman, Charles T. Davis, Erin Hodges, Larisa V. Gubareva
Publikováno v:
J Infect Dis
BACKGROUND. Neuraminidase (NA) inhibitors are the recommended antiviral medications for influenza treatment. However, their therapeutic efficacy can be compromised by NA changes that emerge naturally and/or following antiviral treatment. Knowledge of
Autor:
Todd Davis, Natosha Zanders, David E. Wentworth, Joyce Jones, Larisa V. Gubareva, Juan A. De La Cruz, Anton Chesnokov, Mira C. Patel, Ha T. Nguyen, Vasiliy P. Mishin
Publikováno v:
Antiviral Research. 188:105035
Pimodivir exerts an antiviral effect on the early stages of influenza A virus replication by inhibiting the cap-binding function of polymerase basic protein 2 (PB2). In this study, we used a combination of sequence analysis and phenotypic methods to
Autor:
Larisa V. Gubareva, Juan A. De La Cruz, Anton Chesnokov, Mira C. Patel, Ha T. Nguyen, Lori Lollis, Vasiliy P. Mishin, David E. Wentworth, Vivien G. Dugan
Publikováno v:
J Infect Dis
Susceptibility of influenza A viruses to baloxavir can be affected by changes at amino acid residue 38 in the polymerase acidic (PA) protein. Information on replicative fitness of PA-I38-substituted viruses remains sparse. We demonstrated that substi
Autor:
Jackie Katz, Rebecca Garten, Anton Chesnokov, Vasiliy P. Mishin, Heather Reid, John Barnes, Angela P Campbell, Mira C. Patel, Ha T. Nguyen, Sarah Spencer, Larisa V. Gubareva, Juan A. De La Cruz, Mallory Sinner, David E. Wentworth, Alicia M. Fry
Publikováno v:
Eurosurveillance
The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one
Autor:
Margaret, Okomo-Adhiambo, Alicia M, Fry, Su, Su, Ha T, Nguyen, Anwar Abd, Elal, Elizabeth, Negron, Julie, Hand, Rebecca J, Garten, John, Barnes, Xu, Xiyan, Julie M, Villanueva, Larisa V, Gubareva, Reginald, McClinton
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 1, Pp 136-141 (2015)
Emerging Infectious Diseases
Emerging Infectious Diseases
We report characteristics of oseltamivir-resistant influenza A(H1N1)pdm09 viruses and patients infected with these viruses in the United States. During 2013–14, fifty-nine (1.2%) of 4,968 analyzed US influenza A(H1N1)pdm09 viruses had the H275Y ose
Autor:
Carrie L. Pierce, Maria I. Solano, Adrian R. Woolfitt, Vasiliy P. Mishin, Larisa V. Gubareva, John R. Barr, Tracie L. Williams
Mounting evidence suggests that neuraminidase's functionality extends beyond its classical role in influenza virus infection and that antineuraminidase antibodies offer protective immunity. Therefore, a renewed interest in the development of neuramin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6efb514eeaa30bfb5b26e2f7fa4b9736
https://europepmc.org/articles/PMC5695552/
https://europepmc.org/articles/PMC5695552/
Autor:
Ho-Sheng Wu, Daisuke Tamura, Katrina Sleeman, Larisa V. Gubareva, Juan A. De La Cruz, Alicia M. Fry, Feng-Yee Chang, Julie Villanueva, Henju Marjuki, Nancy J. Cox, Anton Chesnokov, Ha T. Nguyen, Ming-Tsan Liu, Charles T. Davis, Vasiliy P. Mishin, Joyce Jones
Publikováno v:
Journal of Infectious Diseases. 211:249-257
Background Patients contracting influenza A(H7N9) infection often developed severe disease causing respiratory failure. Neuraminidase (NA) inhibitors (NAIs) are the primary option for treatment, but information on drug-resistance markers for influenz
Autor:
Alexander Klimov, Tiffany G. Sheu, Varough M. Deyde, Rebecca Garten, A. Angelica Trujillo, Margaret Okomo-Adhiambo, Larisa V. Gubareva
Publikováno v:
Antimicrobial Agents and Chemotherapy. 54:1102-1110
The M2 blockers amantadine and rimantadine and the neuraminidase (NA) inhibitors (NAIs) oseltamivir and zanamivir are approved by the FDA for use for the control of influenza A virus infections. The 2009 pandemic influenza A (H1N1) viruses (H1N1pdm)